𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson's disease

✍ Scribed by Mary E. Putt; Bernard Ravina

Book ID
114186915
Publisher
Elsevier Science
Year
2002
Tongue
English
Weight
176 KB
Volume
23
Category
Article
ISSN
0197-2456

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Macrogol for the treatment of constipati
Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study
✍ Roberta Zangaglia; Emilia Martignoni; Margaret Glorioso; Maria Ossola; Giulio Ri πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 87 KB πŸ‘ 2 views

## Abstract Chronic constipation is the most frequent symptom of autonomic system involvement in Parkinson's disease (PD). Quite often the symptom is severe and impairs patients' quality of life. The objective of this study is to determine the efficacy and safety of an isosmotic macrogol solution f

Placebo-controlled study of rTMS for the
Placebo-controlled study of rTMS for the treatment of Parkinson's disease
✍ Mikhail P. Lomarev; Sulada Kanchana; William Bara-Jimenez; Meena Iyer; Eric M. W πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 125 KB πŸ‘ 2 views

## Abstract The objective of this study is to assess the safety and efficacy of repetitive transcranial magnetic stimulation (rTMS) for gait and bradykinesia in patients with Parkinson's disease (PD). In a double‐blind placebo‐controlled study, we evaluated the effects of 25 Hz rTMS in 18 PD patien

Rotigotine transdermal patch in early Pa
Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole
✍ Nir Giladi; Babak Boroojerdi; Amos D. Korczyn; David J. Burn; Carl E. Clarke; An πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 167 KB

## Abstract Rotigotine is a new, non‐ergot dopamine agonist formulated in a transdermal delivery system. The present study was to investigate the efficacy and safety of the rotigotine transdermal patch in the treatment of early Parkinson's disease. Patients (n = 561) were randomized to rotigotine,